Search

Your search keyword '"Moum, B."' showing total 475 results
Start Over Author "Moum, B."
475 results on '"Moum, B."'

1. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus

Author

Abreu, M, Ahuja, V, Allez, M, Ananthakrishnan, A, Bemelman, W, Bernstein, C, Braun, J, Chowers, Y, Colombel, J-F, Danese, S, D'Haens, G, D'Hoore, A, Dignass, A, Dotan, I, Dubinsky, M, Ekbom, A, Fleshner, P, Gasche, C, Gassull, MA, Gearry, R, Ghosh, S, Gibson, P, Griffiths, A, Halfvarson, J, Hanauer, S, Harpaz, N, Hart, A, Hibi, T, Kamm, M, Kaplan, G, Kaser, A, Korelitz, B, Kotze, P, Koutroubakis, I, Kruis, W, Lakatos, P, Lewis, J, Lindsay, J, Loftus, E, Louis, E, Lukas, M, Magro, F, Mahadevan, U, Mantzaris, G, Mary, J-Y, McGovern, D, Moum, B, Munkholm, P, Neurath, M, Ng, S, O'Morain, C, Oresland, T, Panaccione, R, Panes, J, Panis, Y, Pemberton, J, Peyrin-Biroulet, L, Prantera, C, Rachmilewitz, D, Ran, Z, Reinisch, W, Remzi, F, Rhodes, J, Riddell, R, Rogler, G, Rubin, D, Sachar, D, Sandborn, W, Sands, B, Sartor, B, Schoelmerich, J, Schreiber, S, Siegel, C, Siegmund, B, Silverberg, M, Söderholm, J, Sood, A, Spinelli, A, Stange, E, Steinwurz, F, Targan, S, Travis, S, Turner, D, Tysk, C, Vatn, M, Vermeire, S, Watanabe, M, Yamamoto, T, Yamamoto-Furusho, J, Ananthakrishnan, Ashwin N, Kaplan, Gilaad G, Bernstein, Charles N, Burke, Kristin E, Lochhead, Paul J, Sasson, Alexa N, Agrawal, Manasi, Tiong, Jimmy Ho Tuan, Steinberg, Joshua, Kruis, Wolfgang, Steinwurz, Flavio, Ahuja, Vineet, Ng, Siew C, Rubin, David T, Colombel, Jean-Frederic, and Gearry, Richard

Published
2022
Full Text
View/download PDF

2. Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study

Author

Lirhus SS, Høivik ML, Moum B, Anisdahl K, and Melberg HO

Subjects
inflammatory bowel disease, incidence, prevalence, real world data, Infectious and parasitic diseases, RC109-216
Abstract

Sandre Svatun Lirhus,1 Marte Lie Høivik,2,3 Bjørn Moum,2,3 Karoline Anisdahl,2,3 Hans Olav Melberg1 1Department of Health Management and Health Economics, University of Oslo, Oslo, Norway; 2Department of Gastroenterology, Oslo University Hospital, Oslo, Norway; 3Institute of Clinical Medicine, University of Oslo, Oslo, NorwayCorrespondence: Sandre Svatun LirhusDepartment of Health Management and Health Economics, University of Oslo, Forskningsveien 3A, Harald Schjelderups Hus, Oslo, 0373, NorwayTel +47 97 58 29 25Email s.s.lirhus@medisin.uio.noBackground: Countries have different diagnostic procedures and treatment regimens for inflammatory bowel disease (IBD) patients. In addition to differences in population characteristics, completeness of data and health registries, different follow-up time and case definitions can have a large impact on estimates of the incidence and prevalence of IBD.Aim: The aim of this study was to use hospital and prescription data to estimate incidence and prevalence of Crohn’s disease (CD) and ulcerative colitis (UC), using different case definitions.Methods: This study used nationwide data from the Norwegian Patient Registry (2008 to 2017) and the Norwegian Prescription Database (2004 to April 2018). Incidence and prevalence were estimated using different case definitions of an IBD patient, varying the number of IBD-related hospital visits and IBD prescriptions required. The base case definition included patients with at least one IBD hospital visit and two IBD prescriptions or two IBD hospital visits.Results: From 2010 to 2017, 16,758 incident IBD patients fulfilled our base case definition, with 6045 diagnosed with CD (36.1%) and 10,713 (63.9%) with UC. For CD, 47.2% of the patients were male while 53.8% of UC patients were male. The base case incidence varied between 14.1 and 16.0 per 100,000 person-years for CD and 24.7 and 28.4/100,000 person-years for UC patients in the years 2010– 2017. When we required at least two IBD hospital visits, not utilizing the prescription data, the CD incidence was 22.3 per 100,000 person-years in 2010 and 13.9 per 100,000 person-years in 2017. For UC, the incidence was 47.4 and 20.6 per 100,000 person-years in 2010 and 2017. In 2017, the prevalence of CD was 0.27% (95% CI: 0.26– 0.27) and 0.50% (95% CI: 0.490– 0.502) for UC.Conclusion: According to our base case definition, the incidence of IBD in Norway was stable from 2010 to 2017. Both the incidence and prevalence of IBD in Norway is among the highest in the world. Moreover, the study also highlights the consequences of different case definitions.Keywords: inflammatory bowel disease, incidence, prevalence, real-world data

Published
2021

3. P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn’s Disease (CD): Results from a large multinational prospective observational study

Author

Louis, E, primary, Sebastien, S, additional, Siegmund, B, additional, Bossuyt, P, additional, Danese, S, additional, de Boer, N, additional, Loftus, E, additional, Moum, B, additional, Peyrin-Biroulet, L, additional, Schreiber, S, additional, Zhou, J, additional, Wernicke, J, additional, Angellotti, E, additional, and Siegel, C, additional

Published
2023
Full Text
View/download PDF

5. P860 The Costs of Inflammatory Bowel Diseases in High-Income Settings

Author

Burisch, J, primary, Zhao, M, additional, Odes, S, additional, De Cruz, P, additional, Vermeire, S, additional, Bernstein, C N, additional, Kaplan, G G, additional, Duricova, D, additional, Greenberg, D, additional, Melberg, H O, additional, Watanabe, M, additional, Ahn, H S, additional, Targownik, L, additional, Pittet, V E H, additional, Annese, V, additional, Park, K, additional, Konstantinos H, K H, additional, Høivik, M L, additional, Krznaric, Z, additional, Chaparro, M, additional, Loftus, E V, additional, Lakatos, P L, additional, Gisbert, J P, additional, Bemelman, W, additional, Moum, B, additional, Gearry, R B, additional, Kappelman, M D, additional, Hart, A, additional, Pierik, M, additional, Andrews, J, additional, Ng, S, additional, D'Inca, R, additional, and Munkholm, P, additional

Published
2023
Full Text
View/download PDF

6. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus

Author

Ananthakrishnan, Ashwin N, primary, Kaplan, Gilaad G, additional, Bernstein, Charles N, additional, Burke, Kristin E, additional, Lochhead, Paul J, additional, Sasson, Alexa N, additional, Agrawal, Manasi, additional, Tiong, Jimmy Ho Tuan, additional, Steinberg, Joshua, additional, Kruis, Wolfgang, additional, Steinwurz, Flavio, additional, Ahuja, Vineet, additional, Ng, Siew C, additional, Rubin, David T, additional, Colombel, Jean-Frederic, additional, Gearry, Richard, additional, Abreu, M, additional, Ahuja, V, additional, Allez, M, additional, Ananthakrishnan, A, additional, Bemelman, W, additional, Bernstein, C, additional, Braun, J, additional, Chowers, Y, additional, Colombel, J-F, additional, Danese, S, additional, D'Haens, G, additional, D'Hoore, A, additional, Dignass, A, additional, Dotan, I, additional, Dubinsky, M, additional, Ekbom, A, additional, Fleshner, P, additional, Gasche, C, additional, Gassull, MA, additional, Gearry, R, additional, Ghosh, S, additional, Gibson, P, additional, Griffiths, A, additional, Halfvarson, J, additional, Hanauer, S, additional, Harpaz, N, additional, Hart, A, additional, Hibi, T, additional, Kamm, M, additional, Kaplan, G, additional, Kaser, A, additional, Korelitz, B, additional, Kotze, P, additional, Koutroubakis, I, additional, Kruis, W, additional, Lakatos, P, additional, Lewis, J, additional, Lindsay, J, additional, Loftus, E, additional, Louis, E, additional, Lukas, M, additional, Magro, F, additional, Mahadevan, U, additional, Mantzaris, G, additional, Mary, J-Y, additional, McGovern, D, additional, Moum, B, additional, Munkholm, P, additional, Neurath, M, additional, Ng, S, additional, O'Morain, C, additional, Oresland, T, additional, Panaccione, R, additional, Panes, J, additional, Panis, Y, additional, Pemberton, J, additional, Peyrin-Biroulet, L, additional, Prantera, C, additional, Rachmilewitz, D, additional, Ran, Z, additional, Reinisch, W, additional, Remzi, F, additional, Rhodes, J, additional, Riddell, R, additional, Rogler, G, additional, Rubin, D, additional, Sachar, D, additional, Sandborn, W, additional, Sands, B, additional, Sartor, B, additional, Schoelmerich, J, additional, Schreiber, S, additional, Siegel, C, additional, Siegmund, B, additional, Silverberg, M, additional, Söderholm, J, additional, Sood, A, additional, Spinelli, A, additional, Stange, E, additional, Steinwurz, F, additional, Targan, S, additional, Travis, S, additional, Turner, D, additional, Tysk, C, additional, Vatn, M, additional, Vermeire, S, additional, Watanabe, M, additional, Yamamoto, T, additional, and Yamamoto-Furusho, J, additional

Published
2022
Full Text
View/download PDF

7. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

Author

Hedin, C, Sado, G, Ndegwa, N, Lytvyak, E, Mason, A, Montano-Loza, A, Gerussi, A, Saffioti, F, Thorburn, D, Nilsson, E, Larsson, G, Moum, B, van Munster, K, Ponsioen, C, Levy, C, Nogueira, N, Bowlus, C, Gotlieb, N, Shibolet, O, Lynch, K, Chapman, R, Rupp, C, Vesterhus, M, Jorgensen, K, Rorsman, F, Schramm, C, Sabino, J, Vermeire, S, Zago, A, Cazzagon, N, Marschall, H, Ytting, H, Ben Belkacem, K, Chazouilleres, O, Almer, S, Bergquist, A, Hedin C. R. H., Sado G., Ndegwa N., Lytvyak E., Mason A., Montano-Loza A., Gerussi A., Saffioti F., Thorburn D., Nilsson E., Larsson G., Moum B. A., van Munster K. N., Ponsioen C. Y., Levy C., Nogueira N. F., Bowlus C. L., Gotlieb N., Shibolet O., Lynch K. D., Chapman R. W., Rupp C., Vesterhus M., Jorgensen K. K., Rorsman F., Schramm C., Sabino J., Vermeire S., Zago A., Cazzagon N., Marschall H. -U., Ytting H., Ben Belkacem K., Chazouilleres O., Almer S., Bergquist A., Hedin, C, Sado, G, Ndegwa, N, Lytvyak, E, Mason, A, Montano-Loza, A, Gerussi, A, Saffioti, F, Thorburn, D, Nilsson, E, Larsson, G, Moum, B, van Munster, K, Ponsioen, C, Levy, C, Nogueira, N, Bowlus, C, Gotlieb, N, Shibolet, O, Lynch, K, Chapman, R, Rupp, C, Vesterhus, M, Jorgensen, K, Rorsman, F, Schramm, C, Sabino, J, Vermeire, S, Zago, A, Cazzagon, N, Marschall, H, Ytting, H, Ben Belkacem, K, Chazouilleres, O, Almer, S, Bergquist, A, Hedin C. R. H., Sado G., Ndegwa N., Lytvyak E., Mason A., Montano-Loza A., Gerussi A., Saffioti F., Thorburn D., Nilsson E., Larsson G., Moum B. A., van Munster K. N., Ponsioen C. Y., Levy C., Nogueira N. F., Bowlus C. L., Gotlieb N., Shibolet O., Lynch K. D., Chapman R. W., Rupp C., Vesterhus M., Jorgensen K. K., Rorsman F., Schramm C., Sabino J., Vermeire S., Zago A., Cazzagon N., Marschall H. -U., Ytting H., Ben Belkacem K., Chazouilleres O., Almer S., and Bergquist A.

Abstract

Background & Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. Results: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P =.035). Factors associated with lower ALP were normal ALP at baseline (P <.01), treatment with adalimumab (P =.090), and treatment in Europe (P =.083). Conclusions: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to inv

Published
2020

8. P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey

Author

Shah, S.C., Khalili, H., Gower-Rousseau, C., Olén, O., Benchimol, E., Lynge, E., Nielsen, K., Ahn, H., Brassard, P., Vutcovici, M., Bitton, A., Bernstein, C., Leddin, D., Tamim, H., Aniwan, S., Chen, C.-Y., Stefánsson, T., Loftus, E.V., Jr., Moum, B., Tang, W., Ng, S., Gearry, R., Sincic, B., Bell, S., Lakatos, P.L., Végh, Z., Ott, C., Kaplan, G., Burisch, J., and Colombel, J.-F.

Published
2017
Full Text
View/download PDF

12. P511 Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)

Author

Wolf, D., Lewis, J.D., Siegmund, B., Lichtenstein, G., Sebastian, S., Siegel, C.A., Louis, E., Haas, T., Nedd, K., Subramanian, S., Aguilar, H., Egan, L., Gasche, C., Doherty, G., Lobo, A., Spearman, D., Patel, A., Moparty, R., Brookes, M., Hebuterne, X., Moum, B., and Dolin, P.

Published
2017
Full Text
View/download PDF

14. P501 Baseline characteristics of Crohnʼs disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)

Author

Siegel, C.A., Lichtenstein, G., Siegmund, B., Lewis, J.D., Wolf, D., Louis, E., Sebastian, S., Hebuterne, X., Bell, A., Söderman, C., Schubert, S., Atreya, R., Polyak, S., Hoque, S., Krummenerl, A., Bokemeyer, B., Krummenerl, T., Shulmann, S., Karlén, P., Moum, B., and Dolin, P.

Published
2017
Full Text
View/download PDF

28. Phenotype at diagnosis predicts recurrence rates in Crohn's disease

Author

Wolters, F.L., Russel, M.G., Sijbrandij, J., Ambergen, T., Odes, S., Riis, L., Langholz, E., Politi, P., Qasim, A., Koutroubakis, I., Tsianos, E., Vermeire, S., Freitas, J., van Zeijl, G., Hoie, O., Bernklev, T., Beltrami, M., Rodriguez, D., Stockbrugger, R.W., and Moum, B.

Subjects
Crohn's disease -- Research, Crohn's disease -- Diagnosis, Crohn's disease -- Risk factors, Phenotype -- Research, Phenotype -- Physiological aspects, Health
Published
2006

29. Crohn's disease: increased mortality 10 years after diagnosis in Europe-wide population based cohort

Author

Wolters, F.L., Russel, M.G., Sijbrandij, J., Schouten, L.J., Odes, S., Riis, L., Munkholm, P., Bodini, P., O'Morain, C., Mouzas, I.A., Tsianos, E., Vermeire, S., Monteiro, E., Limonard, C., Vatn, M., Fornaciari, G., Pereira, S., Moum, B., and Stockbrugger, R.W.

Subjects
Crohn's disease -- Demographic aspects, Crohn's disease -- Patient outcomes, Mortality -- Risk factors, Mortality -- Demographic aspects, Mortality -- Research, Mortality -- Europe, Health
Published
2006

34. OP35 Treatment outcomes of inflammatory bowel disease in the biological era—a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study

Author

Zhao, M, primary, Lördal, M, additional, Langholz, E, additional, Knudsen, T, additional, Voutilainen, M, additional, Høivik, M L, additional, Moum, B, additional, Saebo, B, additional, Haiko, P, additional, Malmgren, C, additional, Coskun, M, additional, Melberg, H O, additional, and Burisch, J, additional

Published
2020
Full Text
View/download PDF

35. P243 Changes in the therapeutic management of inflammatory bowel disease in the biological era – a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study

Author

Zhao, M, primary, Lördal, M, additional, Langholz, E, additional, Knudsen, T, additional, Voutilainen, M, additional, Høivik, M L, additional, Moum, B, additional, Saebo, B, additional, Haiko, P, additional, Malmgren, C, additional, Coskun, M, additional, Melberg, H O, additional, and Burisch, J, additional

Published
2020
Full Text
View/download PDF

36. DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study

Author

Høivik, M, primary, Lördal, M, additional, Burisch, J, additional, Langholz, E, additional, Knudsen, T, additional, Voutilainen, M, additional, Moum, B, additional, Anisdahl, K, additional, Saebo, B, additional, Haiko, P, additional, Malmgren, C, additional, Coskun, M, additional, and Melberg, H O, additional

Published
2020
Full Text
View/download PDF

37. P117 Biomarkers of extracellular matrix remodelling are associated with intestinal fibrosis assessed by magnetic resonance enterography and accumulated intestinal damage (Lémann index): the IBSEN study

Author

Mortensen, J, primary, Lunder, A K, additional, Manon-Jensen, T, additional, Karsdal, M A, additional, Nielsen, M J, additional, Leeming, D J, additional, Hov, J R, additional, Negård, A, additional, Jahnsen, J, additional, Moum, B, additional, Vesterhus, M, additional, Høivik, M L, additional, and Kristensen, V A, additional

Published
2020
Full Text
View/download PDF

48. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Author

Goll, G. L., primary, Jørgensen, K. K., additional, Sexton, J., additional, Olsen, I. C., additional, Bolstad, N., additional, Haavardsholm, E. A., additional, Lundin, K. E. A., additional, Tveit, K. S., additional, Lorentzen, M., additional, Berset, I. P., additional, Fevang, B. T. S., additional, Kalstad, S., additional, Ryggen, K., additional, Warren, D. J., additional, Klaasen, R. A., additional, Asak, Ø., additional, Baigh, S., additional, Blomgren, I. M., additional, Brenna, Ø., additional, Bruun, T. J., additional, Dvergsnes, K., additional, Frigstad, S. O., additional, Hansen, I. M., additional, Hatten, I. S. H., additional, Huppertz‐Hauss, G., additional, Henriksen, M., additional, Hoie, S. S., additional, Krogh, J., additional, Midtgard, I. P., additional, Mielnik, P., additional, Moum, B., additional, Noraberg, G., additional, Poyan, A., additional, Prestegård, U., additional, Rashid, H. U., additional, Strand, E. K., additional, Skjetne, K., additional, Seeberg, K. A., additional, Torp, R., additional, Ystrøm, C. M., additional, Vold, C., additional, Zettel, C. C., additional, Waksvik, K., additional, Gulbrandsen, B., additional, Hagfors, J., additional, Mørk, C., additional, Jahnsen, J., additional, and Kvien, T. K., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results